MorphoSys AG is a German biotechnology company. It is involved in the development and research of antibodies. TecDAX has listed MorphoSys since 2004.
- Headquarters: Planegg, Germany
- Number of employees: 460 (end 2010)
- Founded: 1992, Martinsried, Germany
- morphosys.com
MorphoSys raised upwards of $207.8 million. The company says it’s gathering resources to sink $225 million into the development of its investigational anti-CD19 antibody MOR208 -- a drug it’s developing for diffuse large B cell lymphoma (DLBCL). After its last batch of upbeat data from a Phase II study, MorphoSys, which already received breakthrough status for the drug, said it went straight to regulators hoping for early approval.
